Table 2 Baseline characteristics, treatment, and clinical outcomes of the study population
From: Validation of a new risk score system for non-variceal upper gastrointestinal bleeding
Patient related factor | All patients (n = 905) |
|---|---|
Characteristics | |
Sex | |
 Male | 674 (74.5%) |
 Female | 231 (25.5%) |
Age, years | 65.4 ± 14.7 |
 < 65 | 397 (43.9%) |
 ≥65 | 508 (56.1%) |
Alcohol | |
 Never | 505 (55.8%) |
 Past | 29 (3.1%) |
 Present | 371 (41.0%) |
Smoking | |
 Never | 473 (52.3%) |
 Past | 219 (24.2%) |
 Present | 213 (23.5%) |
ASA score 3 | 488 (53.9%) |
ASA score 4 | 96 (10.6%) |
Comorbidity | |
 Diabetes mellitus | 251 (27.7%) |
 Hypertension | 453 (50.1%) |
 Angina | 81 (9.0%) |
 Cerebral infarction | 156 (17.2%) |
 ARDS | 28 (3.1%) |
 Disseminated malignancy | 87 (9.6%) |
 Liver cirrhosis | 67 (7.4%) |
 Sepsis | 29 (3.2%) |
 DIC | 26 (2.9%) |
Chief complaint at first visit | |
 Melena | 453 (50.1%) |
 Hematemesis | 282 (31.2%) |
 Syncope | 43 (4.8%) |
 Hematochezia | 66 (7.3%) |
 Anemia | 20 (2.2%) |
 Dizziness | 28 (3.1%) |
 Others | 13 (1.4%) |
Endoscopic findings of acute NVUGIB | |
 Gastric ulcer | 614 (67.8%) |
 Duodenal ulcer | 175 (19.3%) |
 Gastroduodenal ulcer | 11 (1.21%) |
 Esophageal ulcer | 7 (0.77%) |
 Mallory-Weiss syndrome | 47 (5.19%) |
 AGML | 4 (0.44%) |
 Angiodysplasia | 22 (2.43%) |
 Hemorrhagic gastritis | 12 (1.32%) |
 Cancer-related bleeding | 13 (1.76%) |
 Forrest classification (IA, IB, IIA) | 607 (67.0%) |
 Forrest classification (IIB, IIC, III) | 298 (32.9%) |
Outcomes | |
 Admission before 8 h | 467 (51.6%) |
 Admission day (mean) | 8.779 day |
 Endoscopy failure at first admission | 35 (3.9%) |
 Endoscopic hemostasis therapy | 735 (81.2%) |
 Endoscopic hemostasis failure | 52 (7.0%) |
 Re-bleeding at 2nd endoscopy | 128 (14.1%) |
 All-cause mortality in hospital in 30 days | 44 (4.9%) |